How does the FcRn blockade mechanism of nipocalimab compare with current standard treatments for myasthenia gravis? So traditionally in myasthenia gravis, like the majority of immune-mediated ...

The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...

Investigational nipocalimab lessened disease severity in generalized myasthenia gravis ... of Neuromuscular and ...

I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue of voluntary muscles.

We do know that myasthenia gravis is an autoimmune condition. So there's an autoimmune response that's directed at the postsynaptic membrane of the neuromuscular junction. And therefore ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Pushpa Narayanaswami is a neuromuscular neurologist ... She is a world-renowned expert in Myasthenia Gravis (MG), and author of the international guidelines for MG. Leading the Myasthenia Gravis ...

and improve access to care for neuromuscular disorders like myasthenia gravis. This new study investigated the impact of COVID-19 on patients with myasthenia gravis, finding that although most ...